AstraZeneca asthma drug hits goal, to enter competitive market – Reuters


Reuters

AstraZeneca asthma drug hits goal, to enter competitive market
Reuters
L) drive to rebuild its portfolio of new medicines received a boost with positive results for an experimental biotech drug for severe asthma that the company previously flagged as a potential $2 billion-a-year seller. Benralizumab, which is likely to
AstraZeneca: Asthma drug trial results positiveMarketWatch
Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe AsthmaNasdaq
TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial ResultsLondon South East (registration) (blog)

all 6 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *